Merck & Co Inc (NYSE: MRK) is reportedly mulling buying cancer-focused biotech Seagen Inc (NASDAQ: SGEN), Wall Street Journal reported citing people familiar with the matter.
If the deal happens, it would be significant, given Seagen’s market value of roughly $28 billion.
According to the report, some people said …
Gain insights, receive dynamic opportunities directly to your inbox. Sign up now…
Catalyzing Investor Engagement, InvestorHyve employs cutting-edge digital marketing solutions, advanced analytics, and an all-encompassing marketing and communications platform to revolutionize corporate interactions with stakeholders. Join us at InvestorHyve and step confidently into the future of corporate engagement
Ready to revolutionize your investor engagement strategy? Join InvestorHyve today and unlock a world of seamless connectivity, personalized interactions, and empowered investor relationships that drive success.
Copyright © 2024. All Rights Reserved.
